In the first half of 2020, global drugmaker stocks had grown in value over what they were at the end of 2019. Companies involved in finding COVID-19 treatments had the biggest gains.
Fifteen drugmakers with the biggest share price gains in 2020:
- Novavax — 1,994 percent share price gain ($4.73 billion market cap gain)
- Adaptimmune — 734 percent share price gain ($1.41 billion market cap gain)
- Inovio Pharmaceuticals —717 percent share price gain (3.93 billion market cap gain)
- Mesoblast — 708 percent share price gain ($0.47 billion market cap gain)
- Cytodyn — 468 percent share price gain ($2.61 billion market cap gain)
- Arcturus Therapeutics — 330 percent share price gain ($0.79 billion market cap gain)
- Moderna — 228 percent share price gain (17.32 market cap gain)
- BioNTech — 100 percent share price gain ($7.47 billion market cap gain)
- Samsung Biologics — 79 percent share price gain ($17.71 billion market cap gain)
- Chugai — 72 percent share price gain ($37.70 billion market cap gain)
- Regeneron — 66 percent share price gain ($28.49 billion market cap gain)
- Lonza — 42 percent share price gain ($11.98 billion market cap gain)
- Eli Lilly — 25 percent share price gain ($30.84 billion market cap gain)
- AbbVie — 11 percent share price gain ($42.09 billion market cap gain)
- AstraZeneca — 6 percent share price gain ($7.99 market cap gain)
More articles on pharmacy:
Patients over 50 may take meds less if pill appearance changes a lot, study says
U.S. cities with the highest, lowest prescription drug costs
US sues Teva for 2nd time in 1 week, this time for alleged price-fixing scheme
